Clinical trial NCT05961956: Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis
Official title: A Proof-of-concept Study With NVDX3, an Osteogenic Implant of Human Allogenic Origin, in the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Spine Fusion in Adults.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Degenerative Lumbar Spondylolisthesis
Lead sponsor: Novadip Biosciences
Sponsor class: INDUSTRY
Collaborators: name: PrimeVigilance
name: Data Investigation Company Europe (DICE)
First posted: 2023-07-27
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Prospective, single arm, single-center clinical study to test NVDX3 in patients suffering from low grade one level degenerative lumbar (L1 - S1) spondylolisthesis. NVDX3 will be implanted during a single surgical intervention.

Detailed description: This is a prospective, single arm, single-center PoC study in adult patients, suffering from a degenerative lumbar (L1-S1) spondylolisthesis, treated by spondylodesis in which NVDX3, an osteogenic implant from human allogeneic origin is used. The screening and implant surgery visits will be used as the reference timepoint respectively for the clinical and the radiological efficacy outcome evaluations.

As per standard of care, patients with DLS are followed up to 12 months post-intervention. In the context of this trial, patient safety and IMP efficacy will be followed up to 24 months post-implant surgery.

Eligibility criteria: Inclusion Criteria:

1. Male or female patients aged ≥18 years to ≤80 years.
2. Patient diagnosed with symptomatic DLS with confirmed:

   1. Classification: Meyerding grade I or II DLS
   2. One vertebral segment within the lumbar region from L1-S1
   3. Availability of AP and LAT X-ray, MRI and/or CT scan at which the diagnosis was made.
3. The estimated volume of targeted disc space to be filled (both inside and around the interbody cage) should not exceed 10cc.
4. Clinically meaningful pain or neurological symptoms with or without claudication confirmed by a preoperative ODI score \>30, which have been unresponsive to a minimum of 3 consecutive months of structured conservative medical management (including at least pain medication, activity modification, and daily exercise).
5. Patient is eligible for surgery by minimally invasive or open transforaminal lumbar interbody fusion (TLIF)3.
6. Patient has understood and accepted to participate in the study according to all study procedures by signing the informed consent.

Exclusion Criteria:

1. History of previously attempted spinal fusion at the same vertebral level, or at a level immediately adjacent to the level intended to undergo the spondylodesis. Decompressive surgery alone (laminectomy) is not an exclusion criterion.
2. Patient with a BMI of ≥35.
3. Presence of clinically significant infection at the target implant site or presence of any systemic infection.
4. History of allergic reaction or any anticipated hypersensitivity to any of the following:

   1. Osteosynthesis materials (eg.cage, screws, rods,...),
   2. Anesthetic agents,
   3. Components of the NVDX3 implant
5. Presence of any auto-immune disease, with exception of well controlled diabetes type-1 or II, or auto-immune thyroid disorders.
6. Positive serology for human immunodeficiency virus (HIV), HBcAb and/or HBsAg.
7. Presence of an active tumor.
8. Documented metabolic bone disease or any disorder, such as but not limited to high-risk osteoporosis, that could interfere with the bone healing and bone metabolism.
9. Documented disease limiting mobility and functional assessments.
10. Chronic, ongoing, or planned use of medications that might affect bone metabolism or bone quality such as bisphosphonates, steroids, methotrexate, anticoagulants, immunosuppressants or immunotherapy.
11. Excessive smoking or history of chronic alcohol or drug abuse within the 12 months prior to screening
12. Use of any investigational drug within 60 days prior to screening.
13. Pregnant women or women of childbearing potential (WOCBP) not agreeing to use effective an effective method of birth control4 during the course of the study. Note: WOCBP including peri-menopausal women who have had a menstrual period within 1 year prior to surgery have to have a negative pregnancy test before entering in the study.
14. Any other psychosocial, mental and physical condition which, in the opinion of the investigator, could interfere with the trial conduct, the patient's compliance or influence interpretation of the results.
15. Patient with historically elevated radiation exposure levels that could in the opinion of the investigator introduce unacceptable radiation risks for the patient, when being accumulated with the radiological examinations planned in this study.

Primary outcomes:
measure: Primary Safety Endpoint
timeFrame: Up to 24 months post implant surgery
Secondary outcomes:
measure: Safety: all acute SAEs and NVDX3 related AEs
timeFrame: Between screening (V1) and 6 weeks post-IS (V4)
measure: Safety: all SAEs and NVDX3 related AEs
timeFrame: Beyond 6 weeks (V4 excluded) until 12 months post-IS
measure: Safety: all SAEs and NVDX3 related AEs
timeFrame: Beyond 12 months (V7 excluded) until 24 months post-IS
measure: Safety: TEAEs
timeFrame: a. Between screening and week 6 (V4 included) b. Between week 6 (V4 excluded) till month 12 (V7 included) c. Between month 12 (V7 excluded) till month 24 (V9 included) d. Full study duration
measure: Safety: related and unexpected (S)AEs
timeFrame: Between screening (v1) till 24 months post-IS
measure: Safety: AESI
timeFrame: Between screening (v1) till 24 months post-IS
measure: Safety: Lab data
timeFrame: Between screening (v1) till 24 months post-IS
measure: Safety: vital signs: physiological parameters
timeFrame: Between screening (v1) till 24 months post-IS
measure: Efficacy: Radiological assessments
timeFrame: a. 4 and 12 months post-IS based on CT compared to Hospital Discharge image acquisition and b. 24-months post-IS based on X-rays compared to the first post-operative X-ray acquisitions taken at 6 weeks post-IS
measure: Efficacy: Radiological assessments
timeFrame: a. 4 and 12 months post-IS based on CT compared to Hospital Discharge image acquisition and b. 24-months post-IS based on X-rays compared to the first post-operative X-ray acquisitions taken at 6 weeks post-IS
measure: Efficacy: Radiological assessments
timeFrame: At Hospital Discharge, 4 and 12 months post-IS
measure: Efficacy: Clinical assessments: investigator questionnaire
timeFrame: At hospital discharge, 6 weeks, 4-, 6-, 12-, 18- and 24-months post-IS
measure: Efficacy: Clinical assessments: patient questionnaire
timeFrame: At hospital discharge, 6 weeks, 4-, 6-, 12-, 18- and 24-months post-IS
measure: Efficacy: Clinical assessments: patient questionnaire
timeFrame: At hospital discharge, 6 weeks, 4-, 6-, 12-, 18- and 24-months post-IS
Other outcomes:
Locations:
city: Luxembourg
country: Luxembourg
facility: Centre Hospitalier de Luxembourg
Study officials:
affiliation: Centre Hospitalier du Luxembourg
name: Anas Ibrahim Ali Dyab, MD
role: PRINCIPAL_INVESTIGATOR
References: